Cargando…
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
BACKGROUND: ARID1A (AT-rich interactive domain containing protein 1A) loss-of-function mutations have been reported in gynecological cancers, including rarer subtypes such as clear cell carcinoma. Preclinical studies indicate that ARID1A mutant cancers display sensitivity to ATR inhibition while tum...
Autores principales: | Banerjee, Susana, Stewart, James, Porta, Nuria, Toms, Christy, Leary, Alexandra, Lheureux, Stephanie, Khalique, Saira, Tai, Jeremy, Attygalle, Ayoma, Vroobel, Katherine, Lord, Christopher J, Natrajan, Rachael, Bliss, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573414/ https://www.ncbi.nlm.nih.gov/pubmed/34518240 http://dx.doi.org/10.1136/ijgc-2021-002973 |
Ejemplares similares
-
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers
por: Khalique, Saira, et al.
Publicado: (2018) -
Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
por: Khalique, Saira, et al.
Publicado: (2022) -
Discordance between positron emission tomography standard uptake value and proliferation index in mantle cell lymphoma: An initial communication
por: Renn, Alexandra, et al.
Publicado: (2021) -
Benchmarking Perturbation-Based Saliency Maps for Explaining Atari Agents
por: Huber, Tobias, et al.
Publicado: (2022) -
OB/GYN secrets /
Publicado: (2003)